Zymeworks' ZW191 shows 64.5% response rate at 6.4 mg/kg in Phase 1 ovarian cancer trial
Bitget2026/10/24 06:30- Zymeworks presented Phase 1 results for ZW191 in platinum-resistant ovarian cancer at ESMO Congress 2026.
- The treatment showed anti-tumor activity across folate receptor alpha expression levels in heavily pretreated patients, with durable responses.
- The lower dose had a more favorable tolerability profile, supporting its consideration for further development.
- Results will guide dose selection, with continued development envisioned through a partnership or strategic collaboration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pyth October Report: ARR Jumps 18.9% as Data Expansion Accelerates
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Crypto prices
More
